In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Sanofi ADR (NASDAQ: SNY) closed at $46.18 down -3.47% from its previous closing price of $47.84. In other words, the price has decreased by -$3.47 from its previous closing price. On the day, 3.49 million shares were traded. SNY stock price reached its highest trading level at $47.47 during the session, while it also had its lowest trading level at $46.1421.
Ratios:
For a deeper understanding of Sanofi ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.42. For the most recent quarter (mrq), Quick Ratio is recorded 0.94 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Exane BNP Paribas on April 15, 2025, initiated with a Outperform rating and assigned the stock a target price of $65.
On March 21, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $65.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 115869777920 and an Enterprise Value of 63402504192. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.53, and their Forward P/E ratio for the next fiscal year is 9.36. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.60 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 1.386 whereas that against EBITDA is 5.248.
Stock Price History:
The Beta on a monthly basis for SNY is 0.49, which has changed by -0.113797724 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, SNY has reached a high of $60.12, while it has fallen to a 52-week low of $44.73. The 50-Day Moving Average of the stock is -5.68%, while the 200-Day Moving Average is calculated to be -10.06%.
Shares Statistics:
For the past three months, SNY has traded an average of 2.27M shares per day and 3097220 over the past ten days. A total of 2.61B shares are outstanding, with a floating share count of 2.43B. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.77% stake in the company. Shares short for SNY as of 1752537600 were 3667009 with a Short Ratio of 1.61, compared to 1749772800 on 4466723. Therefore, it implies a Short% of Shares Outstanding of 3667009 and a Short% of Float of 0.16999999999999998.
Dividends & Splits
According to the company, the forward annual dividend rate for SNY is 2.21, from 3.92 in the trailing year. Against a Trailing Annual Dividend Yield of 0.0819398The stock’s 5-year Average Dividend Yield is 3.78.
Earnings Estimates
The performance of Sanofi ADR (SNY) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $1.01, with high estimates of $1.01 and low estimates of $1.01.
Analysts are recommending an EPS of between $4.58 and $4.48 for the fiscal current year, implying an average EPS of $4.53. EPS for the following year is $5.05, with 7.0 analysts recommending between $5.21 and $4.86.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $12.63B this quarter.It ranges from a high estimate of $13.33B to a low estimate of $12.21B. As of the current estimate, Sanofi ADR’s year-ago sales were $13.44BFor the next quarter, 5 analysts are estimating revenue of $11.3B. There is a high estimate of $12.08B for the next quarter, whereas the lowest estimate is $10.82B.
A total of 13 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $47.3B, while the lowest revenue estimate was $42.99B, resulting in an average revenue estimate of $44.63B. In the same quarter a year ago, actual revenue was $41.08BBased on 11 analysts’ estimates, the company’s revenue will be $47.82B in the next fiscal year. The high estimate is $51.19B and the low estimate is $45.87B.
